390 related articles for article (PubMed ID: 30122895)
1. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Zhang X; Chen Y; Fan L; Ye J; Fan J; Xu X; You D; Liu S; Chen X; Luo P
Drug Des Devel Ther; 2018; 12():2371-2379. PubMed ID: 30122895
[TBL] [Abstract][Full Text] [Related]
2. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast for asthma: Efficacy findings in mechanism of action studies.
Bardin P; Kanniess F; Gauvreau G; Bredenbröker D; Rabe KF
Pulm Pharmacol Ther; 2015 Dec; 35 Suppl():S4-10. PubMed ID: 26296794
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
Field SK
Expert Opin Investig Drugs; 2008 May; 17(5):811-8. PubMed ID: 18447606
[TBL] [Abstract][Full Text] [Related]
5. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
6. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
7. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen LF; Lv XD; Chen WY; Yang Q; Fang ZX; Lu WF
Ir J Med Sci; 2018 Aug; 187(3):731-738. PubMed ID: 29397527
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
12. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
13. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
14. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
15. What is the role of roflumilast in chronic obstructive pulmonary disease?
Lau C; Mehta AC; Hatipoglu U
Cleve Clin J Med; 2017 Jan; 84(1):13-15. PubMed ID: 28084977
[No Abstract] [Full Text] [Related]
16. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Martínez FJ
Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
[No Abstract] [Full Text] [Related]
17. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
19. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Yuan L; Dai X; Yang M; Cai Q; Shao N
Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
